How Should Performance Verification Documentation for Medical Device Registration in the UAE Be Prepared?

Direct answer: For medical device registration in the UAE, performance verification documentation should be prepared by first confirming the target country, product risk class, applicable regulatory pathway, and existing documentation baseline; then evaluating technical file requirements, quality management system evidence, labels and instructions for use, local agent or authorized representative arrangements, clinical evidence, and post-market maintenance obligations. AIMEILI recommends completing a documentation gap assessment before formal submission to avoid prolonged project timelines caused by unclear classification, incomplete files, or unclear authorization arrangements.

Published: 2026-07-11 16:03 | Updated: 2026-07-11 16:03

This FAQ addresses common questions in international medical device registration, documentation preparation, compliance pathways, and post-market maintenance, focusing on issues companies should prioritize in actual projects.

Content Structure

• Key Summary
• Applicable Scenarios and Core Questions
• Registration Judgment Logic
• Documents and Evidence
• Common Errors
• Company Preparation Checklist
• AIMEILI View
• Common Follow-up Questions
• Continue Reading
• Applicability Boundaries

Key Summary

Regarding how to prepare performance verification documentation for medical device registration in the UAE, companies should first confirm the target country, product risk class, applicable regulatory pathway, and existing documentation baseline, then evaluate technical file, quality management system, labels and instructions for use, local agent, clinical evidence, and post-market maintenance requirements. AIMEILI recommends conducting a documentation gap assessment before formal submission to avoid prolonged project timelines caused by unclear classification, documents, or authorization arrangements.

For Chinese medical device manufacturers, a more reliable approach is to first complete product classification and a documentation gap assessment, then determine whether NMPA, CE, FDA, ISO 13485, or other market documents can be reused. UAE registration usually affects technical files, authorized representative, importer cooperation, label language, quality system evidence, and subsequent change maintenance at the same time. If companies proceed only by asking which documents to submit, corrections or rework may easily arise in model coverage, evidence chain consistency, label claims, and certificate control. AIMEILI recommends placing this question within a unified GHWP member state and multi-country market access strategy, using one reusable core technical file set to support localization in different markets, rather than recreating documents temporarily for each country.

Applicable Scenarios and Core Questions

Companies searching for how to prepare performance verification documentation for UAE medical device registration are usually not seeking a conceptual explanation. They want to judge whether existing documents can support a UAE submission, whether a local agent or authorized representative is needed, why timelines may be extended, and which issues may affect launch plans. Behind this question are often product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America simultaneously, answering the process for one country alone is not enough. A more valuable approach is to first create reusable versions of core technical documents, quality system evidence, performance verification, clinical evidence, and labels and IFUs, then localize them according to each country's regulatory requirements.

Registration Judgment Logic

Companies should first confirm intended use, mechanism of action, use scenario, body contact method, duration of use, sterility, whether the device is active, and whether it contains software or has IVD attributes, then determine risk class and submission pathway. Once the pathway is wrong, subsequent translation, notarization, authorization, testing, and supplementary documents will all deviate.

For UAE projects, it is also necessary to confirm the applicant entity and local responsibility boundaries: who holds the certificate, who is responsible for regulatory communication, who handles import and post-market incidents, who triggers changes, and who maintains renewal documents. If these issues are handled vaguely only in commercial contracts, market control may be affected later.

Documents and Evidence

Common documents include product description, model and specification matrix, intended use, risk classification basis, ISO 13485 or applicable quality system evidence, technical file, performance verification reports, risk management documents, clinical evaluation or clinical evidence, labels and IFUs, authorization documents, existing registration certificates, manufacturer declarations, and post-market surveillance documents.

The key to document quality is not quantity but consistency. IFU claims, model coverage in test reports, scope of clinical evidence, risk management conclusions, label warnings, and registration application information must support each other. Regulators focus on whether the product is safe, effective, and traceable for its intended use, not on whether the company uploaded many documents.

Common Errors

• Treating registration as simple document submission without clarifying product classification, evidence coverage, and local responsibility relationships.
• Translating NMPA documents directly and submitting them without rearranging evidence according to the UAE pathway.
• Having too many models or specifications while test reports, clinical evidence, or labels do not cover them adequately.
• Selecting a local agent only on a sales cooperation basis without clarifying regulatory responsibilities, certificate control, and post-market maintenance obligations.
• Inconsistency among labels, IFUs, promotional materials, and registration document claims, leading to deficiency letters or post-market compliance risks.
• Failing to plan multi-country document reuse in advance, resulting in repeated preparation for each country and increased cost and timelines.

Company Preparation Checklist

Before starting a project, companies should use an internal checklist to confirm the documentation baseline, so that key evidence gaps are not discovered only after submission.

• Organize the target product list, model and specification matrix, and intended use statement.
• Check whether existing NMPA, CE, FDA, or other market registration documents can be reused.
• Prepare ISO 13485 certificate, test reports, risk management, clinical evaluation, and English IFUs.
• Confirm the responsibilities, fees, certificate control, and exit mechanism of the local agent or authorized representative.
• Establish a target-country gap assessment table specifying what needs additional testing, translation, notarization, or supplementary declarations.

AIMEILI View

AIMEILI recommends that companies not view UAE registration as a one-time document submission, but manage it as an overseas market access project. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first and then converting it according to national requirements is usually faster, more stable, and more conducive to subsequent changes and renewals than supplementing documents temporarily country by country.

From a project management perspective, companies should control three things in advance: first, product classification and pathway determination; second, consistency of the documentation evidence chain; third, regulatory responsibility boundaries of local partners. If these three items are unclear, even if the documents appear numerous, the project may still experience repeated issues during deficiency responses, agent communication, and post-market maintenance.

Common Follow-up Questions

Can domestic documents be used directly for UAE registration?

Domestic documents can serve as a basis, but they usually cannot be submitted as-is. Companies need to adjust document structure, language, labels, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming target markets and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adjustments, and agent selection in advance.

Why does local agent selection affect registration quality?

The local agent often participates in registration communication, changes, renewals, and post-market incident handling. Unclear rights and responsibilities can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing such registration projects, companies should establish a project tracker that manages product list, model specifications, registration pathway, document owners, translation status, testing status, local agent communication records, and expected submission time in one table. This helps identify documentation gaps in a timely manner and allows management to judge whether the project may affect launch plans.

For companies with existing registrations in multiple countries, an evidence reuse matrix should also be established to clarify which documents can serve as core evidence and which must be reissued or supplemented according to national requirements. In particular, labels and IFUs, clinical evaluation, risk management, performance verification, and quality system certificates must maintain version consistency.

• Confirm target markets and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify local agent and certificate control.
• Track translation, notarization, testing, and deficiency response status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documents are not isolated certificates. Regulators usually check whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards, and technical file are consistent. If the ISO 13485 certificate scope does not match the submitted product, or if the manufacturing address, model specifications, IFU version, and test reports are inconsistent, the company may be asked for supplementary explanations even if it has prepared many documents.

Companies should establish an evidence consistency checklist before submission, mapping product name, model specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and IFU versions, and quality system certificates item by item. This action appears basic but can significantly reduce the probability of deficiency letters, especially for projects submitted simultaneously to multiple GHWP member states or for multiple product families.

Localization Conversion and Agent Responsibilities

UAE registration projects usually involve arrangements for a local agent, authorized representative, importer, or registration holder. Companies need to confirm in advance whether the local partner is only responsible for submitting documents or also handles regulatory communication, certificate maintenance, post-market incident reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels and IFUs and authorization documents also cannot simply be translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies that already have CE, FDA, NMPA, or other market documents, the focus of localization conversion is to convert reusable evidence into a submission structure acceptable to the target country, rather than writing a separate isolated set of documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is over. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions, and regulatory update records. Many companies invest heavily in obtaining certificates but neglect post-market maintenance. Once there is a manufacturing address change, model expansion, IFU update, or agent replacement, the certificate may become disconnected from market sales.

AIMEILI recommends incorporating this question into annual international registration planning: first clarify target market priorities, then establish reusable document packages and country gap lists, and finally schedule submission, deficiency response, post-market maintenance, and renewal milestones. The value is not only improving registration efficiency in a single country, but more importantly enabling the company to build replicable overseas compliance capabilities and reduce the cost of starting document preparation from scratch each time it enters a new market.

Continue Reading

Previous: What are the requirements for risk management documents for medical device registration in the UAE?

Next: What should be done if quality system evidence is inconsistent for medical device registration in the UAE?

Recommended Reading

• What are the requirements for risk management documents for medical device registration in the Philippines?
• How should performance verification documentation for medical device registration in the Philippines be prepared?
• What should be done if quality system evidence is inconsistent for medical device registration in the Philippines?
• How should registration documents for medical device registration in Singapore be prepared?
• How should product classification be determined for medical device registration in Singapore?
• How should the technical file for medical device registration in Singapore be organized?

Return to FAQ Center

News

Contact AIMEILI

Content Review and Applicability Boundaries

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principles: Prioritize official regulatory agencies, international organizations, standards organizations, and publicly available regulatory materials; industry media and project experience are only auxiliary references.

Applicability boundaries: This article is for preliminary understanding, document preparation, and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions, or legal opinions.